Federal award (PURCHASE ORDER, fiscal year 2023)
Recipient: GLYPHIC BIOTECHNOLOGIES, INC.
Awarding agency: Department of Defense / Defense Health Agency
Funding agency: Department of Defense / Defense Health Agency
Period of performance: 2024-04-08 to 2024-11-07
Current total value of award: $249993.28
Description: MEDICAL R AND D PURCHASE ORDER FOR A DHA STTR PHASE I, PROPOSAL NO. H23C-001-0042, TITLED, "DEVELOPMENT OF ANTI-GLYCAN ANTIBODIES AGAINST MULTI-DRUG RESISTANT ESKAPE WOUND PATHOGENS"